H.I.G. Capital News

Contact:

Corporate Inquiries:
Susan Sharpe
Corporate Communications Manager
(919) 313-4761
ssharpe@tranzyme.com

Investor Inquiries:
David Carey
Lazar Partners, Ltd.
(212) 867-1768
dcarey@lazarpartners.com

Tranzyme Pharma's Richard Eisenstadt Wins Triangle Business Journal CFO of the Year Award

RESEARCH TRIANGLE PARK, N.C. - July 20, 2011 - Tranzyme Pharma (Nasdaq:TZYM) today announced that its Chief Financial Officer, Richard Eisenstadt, has been honored as a Triangle Business Journal CFO of the Year for 2011.

"We're all very proud of Rich and congratulate him on being recognized as a top CFO in the Raleigh-Durham area," said Vipin K. Garg, PhD, President and CEO, Tranzyme Pharma. "Rich's financial leadership has been valuable throughout his tenure, and was exceptional during Tranzyme's transition to becoming a publicly-traded company earlier this year."

Since joining Tranzyme Pharma in 2003, Mr. Eisenstadt has secured more than $140 million of new capital, including net proceeds of $51.4 million as part of the company's initial public offering on April 1, 2011. As a result, Tranzyme Pharma is well positioned to advance the development of its drug candidates focused on upper GI motility therapeutics.

The CFO of the year awards program recognizes outstanding financial professionals for their fiscal stewardship, and their community service record in the past 12 months.

Mr. Eisenstadt was selected from a field of 22 finalists. In addition to an awards ceremony held on July 14, honorees were profiled in a special section of the Triangle Business Journal published on July 15th.For more information about the CFO of the year program, visit: www.bizjournals.com/triangle.

About Tranzyme Pharma
Tranzyme Pharma is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. All of Tranzyme's product candidates have been discovered using its proprietary drug discovery (chemistry) technology, MATCH™, which enables the construction of synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. www.tranzyme.com The Tranzyme, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=9438

Forward-Looking Statements
Statements in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section27A of the Securities Act and Section21E of the Securities Exchange Act, which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions.These include statements regarding the continued development of our drug candidates.We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section27A of the Securities Act and Section21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made.Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks related to enrollment and successful completion of our trials, risk of unforeseen side effects, risks related to our collaborations and risks related to regulatory approval of new drug candidates. Further information on these and other factors that could affect the company's financial results is contained in our public filings with the Securities and Exchange Commission (SEC) from time to time, including our Registration Statement on Form S-1 (Registration No. 333-170749), which was declared effective by the Securities and Exchange Commission on April 1, 2011, and subsequent filings with the SEC.Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.